Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

Topical Calcipotriol (vitamin D derivative) may help with hair regrowth, especially for alopecia areata. The user wonders if adding classic vitamin D to lotions like Minoxidil could have a similar effect.

Person 1, with slow hair loss, might need less finasteride than Person 2, who is balding rapidly. The suggested doses are 0.25 mg finasteride three times a week for Person 1 and 1 mg daily for Person 2.

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

Hair loss discussion; treatments include 0.5mg finasteride daily and 1.5mm dr pen weekly on scalp. Monthly progress updates planned.

The conversation discusses using a multimodal approach to treat androgenic alopecia, including substances like gamma-linolenic acid, DHA, sulforaphane, melatonin, cetirizine, astaxanthin, fisetin, apigenin, curcumin, limonene, genistein, and berberine. Users also mention using ketoconazole, minoxidil, and low-level laser therapy (LLLT) as part of their hair loss treatment regimens.

Diffuse thinning is unpredictable, and while some suggest treatments like finasteride or dutasteride, others emphasize acceptance as hair loss may continue. Some users share personal experiences with treatments like nizoral, scalp massage, and lifestyle changes, but results vary.

A new hair cloning breakthrough suggests a potential cure for hair loss, though skepticism remains about its availability and cost. Users discuss the possibility of unlimited hair grafts for transplants and express hope for future developments.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

Epristeride is a selective 5 alpha reductase type 2 inhibitor that may reduce scalp DHT similarly to finasteride, with potentially fewer side effects. It is suggested that combining epristeride with finasteride or dutasteride could enhance hair loss treatment effectiveness.

Hair loss is primarily genetic, and nutrient deficiencies are unlikely to be the cause. DHT inhibitors can slow hair loss, but concerns about side effects are common.

The user is experiencing severe hair loss after surgery and stress, with thinning all over the head, including the sides and neck. They are unsure if it's due to DUPA or alopecia areata incognita, and doctors have not observed miniaturization.

Using a combination of micro-needling and exosome injections as a potential treatment for male pattern baldness, which could result in 50% or more regrowth.

The conversation is about sourcing and using topical melatonin for retrograde alopecia. Users discuss purchasing options and potential benefits for hair growth.

The conversation discusses the use of 0.1% latanoprost for hair regrowth, with concerns about cost and dependency. The user currently uses dutasteride and oral minoxidil and is considering adding latanoprost to their regimen.

The conversation is about someone seeking advice on choosing between stem cell therapy and PRP for treating hair loss, asking for personal results, side effects, overall satisfaction, and recommendations from others.

The conversation discusses hair thinning and treatments like Minoxidil, finasteride, and RU58841. The user is concerned about distinguishing between natural hair parting and actual thinning.

The user is unsatisfied with their hair transplant and is considering another transplant, PRP, exosomes, or stem cells. They currently use topical minoxidil, dutasteride, and tretinoin.

Clascoterone, a topical anti-androgen for hair loss, is expected to be released in late 2026 or early 2027.

The conversation is about finding a suitable hairbrush for diffuse thinning hair without causing separation or flattening. The user is using oral dutasteride, minoxidil foam, Nizoral, microneedling, and Pura D’or shampoo and conditioner.

The conversation discusses a 24-year-old Korean man's progress with hair loss treatments over 8-9 months, with specific treatments not mentioned due to redacted information. Users are commenting on the effectiveness and inquiring if Asians have better results with hair loss treatments.

The conversation discusses whether Pyrilutamide from Koshine is different from Anageninc and if it's effective for hair loss. It also questions if sticking to RU58841 would be better.

PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.

The conversation discusses the use of topical peptides ahk-cu and ghk-cu for hair loss. One user reported that while these peptides made their hair look thicker and improved scalp health, they did not notice significant hair growth.

A 17-year-old is addressing hair loss with finasteride, topical minoxidil, and microneedling. They are considering adding GHK-Cu to their regimen, but others advise caution with finasteride due to age.

Topical finasteride is currently more effective than pyrilutamide for hair loss. Combining treatments like topical finasteride and pyrilutamide may enhance results due to different mechanisms.

A 24-year-old male experienced hair loss despite using minoxidil and finasteride, later switching to dutasteride, higher-dose minoxidil, iron supplements, and derma stamping, which initially improved his condition. However, after moving to a stressful environment and undergoing minor surgery, his hair loss rapidly increased, particularly on one side of his temple.

The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.

Topical spironolactone is discussed for hair loss treatment, with mentions of DIY solutions and dermatologist compounding. Users inquire about regrowth and sourcing the treatment.